Tear Stimulation Forte

Aconitum Napellus, Nutmeg, Arsenic Trioxide, Aluminum Oxide, Zinc, Euphrasia Stricta, Sodium Chloride


Natural Ophthalmics, Inc
Human Otc Drug
NDC 68770-114
Tear Stimulation Forte also known as Aconitum Napellus, Nutmeg, Arsenic Trioxide, Aluminum Oxide, Zinc, Euphrasia Stricta, Sodium Chloride is a human otc drug labeled by 'Natural Ophthalmics, Inc'. National Drug Code (NDC) number for Tear Stimulation Forte is 68770-114. This drug is available in dosage form of Liquid. The names of the active, medicinal ingredients in Tear Stimulation Forte drug includes Aconitum Napellus - 15 [hp_C]/mL Aluminum Oxide - 14 [hp_X]/mL Arsenic Trioxide - 12 [hp_X]/mL Euphrasia Stricta - 5 [hp_X]/mL Nutmeg - 6 [hp_X]/mL Sodium Chloride - 15 [hp_C]/mL Zinc - 11 [hp_X]/mL . The currest status of Tear Stimulation Forte drug is Active.

Drug Information:

Drug NDC: 68770-114
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Tear Stimulation Forte
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Otc Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Aconitum Napellus, Nutmeg, Arsenic Trioxide, Aluminum Oxide, Zinc, Euphrasia Stricta, Sodium Chloride
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Natural Ophthalmics, Inc
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Liquid
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:ACONITUM NAPELLUS - 15 [hp_C]/mL
ALUMINUM OXIDE - 14 [hp_X]/mL
ARSENIC TRIOXIDE - 12 [hp_X]/mL
EUPHRASIA STRICTA - 5 [hp_X]/mL
NUTMEG - 6 [hp_X]/mL
SODIUM CHLORIDE - 15 [hp_C]/mL
ZINC - 11 [hp_X]/mL
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:OPHTHALMIC
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: UNAPPROVED HOMEOPATHIC
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 10 Jun, 2021
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 16 Jan, 2025
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Listing Expiration Date: 31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:Natural Ophthalmics, Inc
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
NUI:N0000185371
N0000185375
N0000175629
N0000184306
M0000728
M0016962
M0006342
M0008672
M0516536
Unique identifier applied to a drug concept within the National Drug File Reference Terminology (NDF-RT).
UNII:U0NQ8555JD
LMI26O6933
S7V92P67HO
C9642I91WL
AEE24M3MQ9
451W47IQ8X
J41CSQ7QDS
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.
Pharmacologic Class EPC:Non-Standardized Food Allergenic Extract [EPC]
Non-Standardized Plant Allergenic Extract [EPC]
Established pharmacologic class associated with an approved indication of an active moiety (generic drug) that the FDA has determined to be scientifically valid and clinically meaningful. Takes the form of the pharmacologic class, followed by `[EPC]` (such as `Thiazide Diuretic [EPC]` or `Tumor Necrosis Factor Blocker [EPC]`.
Pharmacologic Class PE:Increased Histamine Release [PE]
Cell-mediated Immunity [PE]
Physiologic effect or pharmacodynamic effect—tissue, organ, or organ system level functional activity—of the drug’s established pharmacologic class. Takes the form of the effect, followed by `[PE]` (such as `Increased Diuresis [PE]` or `Decreased Cytokine Activity [PE]`.
Pharmacologic Class CS:Allergens [CS]
Plant Proteins [CS]
Dietary Proteins [CS]
Food Additives [CS]
Seed Storage Proteins [CS]
Chemical structure classification of the drug product’s pharmacologic class. Takes the form of the classification, followed by `[Chemical/Ingredient]` (such as `Thiazides [Chemical/Ingredient]` or `Antibodies, Monoclonal [Chemical/Ingredient].
Pharmacologic Class:Allergens [CS]
Cell-mediated Immunity [PE]
Dietary Proteins [CS]
Food Additives [CS]
Increased Histamine Release [PE]
Increased Large Intestinal Motility [PE]
Inhibition Large Intestine Fluid/Electrolyte Absorption [PE]
Non-Standardized Food Allergenic Extract [EPC]
Non-Standardized Plant Allergenic Extract [EPC]
Osmotic Activity [MoA]
Osmotic Laxative [EPC]
Plant Proteins [CS]
Seed Storage Proteins [CS]
These are the reported pharmacological class categories corresponding to the SubstanceNames listed above.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
68770-114-101 BOTTLE, DROPPER in 1 PACKAGE (68770-114-10) / 10 mL in 1 BOTTLE, DROPPER10 Jun, 2021N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Purpose:

Homeopathic purpose pulsatilla 8x } sepia 8x } euphrasia (eyebright) 5x } alumina 10x } dry eyes arsenicum album 12x } nux mosch 6x } zincum met 10x }

Product Elements:

Tear stimulation forte aconitum napellus, nutmeg, arsenic trioxide, aluminum oxide, zinc, euphrasia stricta, sodium chloride water polysorbate 80 citric acid monohydrate sodium chloride sodium cation aconitum napellus aconitum napellus euphrasia stricta euphrasia stricta aluminum oxide aluminum oxide arsenic trioxide arsenic cation (3+) nutmeg nutmeg zinc zinc

Indications and Usage:

Uses according to homeopathic principles these drops are indicated for acute or chronic dry eyes, sjögren’s or excessive watering secondary to dry eye.* * claims are based on traditonal homeopathic practce, not accepted medical evidence. not fda evaluated.

Warnings:

Warnings for ophthalmic use.

Do Not Use:

Warnings for ophthalmic use.

Dosage and Administration:

Directions instill 1-3 drops in the eye. use several times per day as needed.

Stop Use:

Stop use and ask a doctor if stop use and ask a doctor if : you experience eye pain, changes in vision, continued redness or irritation of the eye. the condition worsens. symptoms last longer than 72 hours.

Package Label Principal Display Panel:

Label image label carton


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.